Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Cantharidin (Primary)
- Indications Molluscum contagiosum
- Focus Registrational; Therapeutic Use
- Acronyms CAMP-2
- Sponsors Verrica Pharmaceuticals
- 21 Jul 2023 According to a Verrica Pharmaceuticals media release, based on the data of CAMP-1 and CAMP-2 studies, the USA Food and Drug Administration (FDA) approval of YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.
- 27 Feb 2023 According to a Verrica Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) accepted for resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum and assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 23, 2023.
- 11 Aug 2022 According to a Verrica Pharmaceuticals media release, company expect to be able to resubmit the NDA for VP-102 for the treatment of molluscum contagiosum (molluscum) in the first quarter of 2023.